Hepatitis B vaccine in hemodialysis patients with hepatitis C viral infection

Chi Hung Cheng, Chiu Ching Huang, Mei Ling Leu, Chun Yi Fan Chiang, Mai Szu Wu, Ping Chin Lai

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Patients on hemodialysis therapy are at a relatively high risk of exposure to hepatitis B virus (HBV) infection. The prevalence of hepatitis C virus (HCV) infection is even higher and was reported as 33.2% in Taiwan. Although the efficacy of hepatitis B vaccine was well documented, the vaccination schedule in hemodialysis patients is not clearly defined. And under such a high prevalence of HCV infection, little is known about the influence of HCV imposing on HBV vaccination. We studied 50 chronic hemodialysis patients who were serologically negative for the hepatitis B surface antigen (HBsAg), the antibody to the hepatitis B surface antigen (anti-HBs) and the antibody to the hepatitis B core antigen (anti-HBc); 26 of them were positive for the antibody to hepatitis C virus (anti-HCV) test. Recombinant hepatitis B vaccine (Engerix-B) 40 μg per dose was administered by the intramuscular route at deltoid region at 0, 1, 2, 6 and 12 months respectively to all the patients. Forty-six patients had completed the study. The effective seroconversion rate (serum anti-HBs titer > 10 mIU ml -1) at 1 month after the final vaccine was 76.1% (35/46). The effective conversion rates of the anti-HCV (+) group to the anti-HCV(-) were 75% versus 77.3% (P=0.857). Geometric mean anti-HBs titers were 177.67 mIU ml -1 versus 189.28 mIU ml -1 (P = 0.867). Our results showed that five-dose injections of HBV vaccine do not present a superior outcome to the four-dose regimen comparing to published data. The status of positivity of anti-HCV do not pose an suboptimal effect on HBV vaccination of hemodialysis patients.

Original languageEnglish
Pages (from-to)1353-1357
Number of pages5
JournalVaccine
Volume15
Issue number12-13
DOIs
Publication statusPublished - Aug 1997
Externally publishedYes

Fingerprint

hepatitis C
Hepatitis B Vaccines
hemodialysis
Hepatitis C virus
hepatitis B
Virus Diseases
Hepatitis C
Renal Dialysis
Hepatitis C Antibodies
vaccines
Hepatitis B virus
antibodies
Hepacivirus
infection
Vaccination
Hepatitis B Surface Antigens
vaccination
Hepatitis B Core Antigens
dosage
Synthetic Vaccines

Keywords

  • Hemodialysis patients
  • Hepatitis B vaccine
  • Hepatitis C infection
  • Immunogenicity

ASJC Scopus subject areas

  • Immunology
  • Microbiology
  • Virology
  • Infectious Diseases
  • Public Health, Environmental and Occupational Health
  • veterinary(all)

Cite this

Cheng, C. H., Huang, C. C., Leu, M. L., Chiang, C. Y. F., Wu, M. S., & Lai, P. C. (1997). Hepatitis B vaccine in hemodialysis patients with hepatitis C viral infection. Vaccine, 15(12-13), 1353-1357. https://doi.org/10.1016/S0264-410X(97)00037-6

Hepatitis B vaccine in hemodialysis patients with hepatitis C viral infection. / Cheng, Chi Hung; Huang, Chiu Ching; Leu, Mei Ling; Chiang, Chun Yi Fan; Wu, Mai Szu; Lai, Ping Chin.

In: Vaccine, Vol. 15, No. 12-13, 08.1997, p. 1353-1357.

Research output: Contribution to journalArticle

Cheng, CH, Huang, CC, Leu, ML, Chiang, CYF, Wu, MS & Lai, PC 1997, 'Hepatitis B vaccine in hemodialysis patients with hepatitis C viral infection', Vaccine, vol. 15, no. 12-13, pp. 1353-1357. https://doi.org/10.1016/S0264-410X(97)00037-6
Cheng, Chi Hung ; Huang, Chiu Ching ; Leu, Mei Ling ; Chiang, Chun Yi Fan ; Wu, Mai Szu ; Lai, Ping Chin. / Hepatitis B vaccine in hemodialysis patients with hepatitis C viral infection. In: Vaccine. 1997 ; Vol. 15, No. 12-13. pp. 1353-1357.
@article{502dff299ceb45b094801472f38af9c2,
title = "Hepatitis B vaccine in hemodialysis patients with hepatitis C viral infection",
abstract = "Patients on hemodialysis therapy are at a relatively high risk of exposure to hepatitis B virus (HBV) infection. The prevalence of hepatitis C virus (HCV) infection is even higher and was reported as 33.2{\%} in Taiwan. Although the efficacy of hepatitis B vaccine was well documented, the vaccination schedule in hemodialysis patients is not clearly defined. And under such a high prevalence of HCV infection, little is known about the influence of HCV imposing on HBV vaccination. We studied 50 chronic hemodialysis patients who were serologically negative for the hepatitis B surface antigen (HBsAg), the antibody to the hepatitis B surface antigen (anti-HBs) and the antibody to the hepatitis B core antigen (anti-HBc); 26 of them were positive for the antibody to hepatitis C virus (anti-HCV) test. Recombinant hepatitis B vaccine (Engerix-B) 40 μg per dose was administered by the intramuscular route at deltoid region at 0, 1, 2, 6 and 12 months respectively to all the patients. Forty-six patients had completed the study. The effective seroconversion rate (serum anti-HBs titer > 10 mIU ml -1) at 1 month after the final vaccine was 76.1{\%} (35/46). The effective conversion rates of the anti-HCV (+) group to the anti-HCV(-) were 75{\%} versus 77.3{\%} (P=0.857). Geometric mean anti-HBs titers were 177.67 mIU ml -1 versus 189.28 mIU ml -1 (P = 0.867). Our results showed that five-dose injections of HBV vaccine do not present a superior outcome to the four-dose regimen comparing to published data. The status of positivity of anti-HCV do not pose an suboptimal effect on HBV vaccination of hemodialysis patients.",
keywords = "Hemodialysis patients, Hepatitis B vaccine, Hepatitis C infection, Immunogenicity",
author = "Cheng, {Chi Hung} and Huang, {Chiu Ching} and Leu, {Mei Ling} and Chiang, {Chun Yi Fan} and Wu, {Mai Szu} and Lai, {Ping Chin}",
year = "1997",
month = "8",
doi = "10.1016/S0264-410X(97)00037-6",
language = "English",
volume = "15",
pages = "1353--1357",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier BV",
number = "12-13",

}

TY - JOUR

T1 - Hepatitis B vaccine in hemodialysis patients with hepatitis C viral infection

AU - Cheng, Chi Hung

AU - Huang, Chiu Ching

AU - Leu, Mei Ling

AU - Chiang, Chun Yi Fan

AU - Wu, Mai Szu

AU - Lai, Ping Chin

PY - 1997/8

Y1 - 1997/8

N2 - Patients on hemodialysis therapy are at a relatively high risk of exposure to hepatitis B virus (HBV) infection. The prevalence of hepatitis C virus (HCV) infection is even higher and was reported as 33.2% in Taiwan. Although the efficacy of hepatitis B vaccine was well documented, the vaccination schedule in hemodialysis patients is not clearly defined. And under such a high prevalence of HCV infection, little is known about the influence of HCV imposing on HBV vaccination. We studied 50 chronic hemodialysis patients who were serologically negative for the hepatitis B surface antigen (HBsAg), the antibody to the hepatitis B surface antigen (anti-HBs) and the antibody to the hepatitis B core antigen (anti-HBc); 26 of them were positive for the antibody to hepatitis C virus (anti-HCV) test. Recombinant hepatitis B vaccine (Engerix-B) 40 μg per dose was administered by the intramuscular route at deltoid region at 0, 1, 2, 6 and 12 months respectively to all the patients. Forty-six patients had completed the study. The effective seroconversion rate (serum anti-HBs titer > 10 mIU ml -1) at 1 month after the final vaccine was 76.1% (35/46). The effective conversion rates of the anti-HCV (+) group to the anti-HCV(-) were 75% versus 77.3% (P=0.857). Geometric mean anti-HBs titers were 177.67 mIU ml -1 versus 189.28 mIU ml -1 (P = 0.867). Our results showed that five-dose injections of HBV vaccine do not present a superior outcome to the four-dose regimen comparing to published data. The status of positivity of anti-HCV do not pose an suboptimal effect on HBV vaccination of hemodialysis patients.

AB - Patients on hemodialysis therapy are at a relatively high risk of exposure to hepatitis B virus (HBV) infection. The prevalence of hepatitis C virus (HCV) infection is even higher and was reported as 33.2% in Taiwan. Although the efficacy of hepatitis B vaccine was well documented, the vaccination schedule in hemodialysis patients is not clearly defined. And under such a high prevalence of HCV infection, little is known about the influence of HCV imposing on HBV vaccination. We studied 50 chronic hemodialysis patients who were serologically negative for the hepatitis B surface antigen (HBsAg), the antibody to the hepatitis B surface antigen (anti-HBs) and the antibody to the hepatitis B core antigen (anti-HBc); 26 of them were positive for the antibody to hepatitis C virus (anti-HCV) test. Recombinant hepatitis B vaccine (Engerix-B) 40 μg per dose was administered by the intramuscular route at deltoid region at 0, 1, 2, 6 and 12 months respectively to all the patients. Forty-six patients had completed the study. The effective seroconversion rate (serum anti-HBs titer > 10 mIU ml -1) at 1 month after the final vaccine was 76.1% (35/46). The effective conversion rates of the anti-HCV (+) group to the anti-HCV(-) were 75% versus 77.3% (P=0.857). Geometric mean anti-HBs titers were 177.67 mIU ml -1 versus 189.28 mIU ml -1 (P = 0.867). Our results showed that five-dose injections of HBV vaccine do not present a superior outcome to the four-dose regimen comparing to published data. The status of positivity of anti-HCV do not pose an suboptimal effect on HBV vaccination of hemodialysis patients.

KW - Hemodialysis patients

KW - Hepatitis B vaccine

KW - Hepatitis C infection

KW - Immunogenicity

UR - http://www.scopus.com/inward/record.url?scp=0030983864&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030983864&partnerID=8YFLogxK

U2 - 10.1016/S0264-410X(97)00037-6

DO - 10.1016/S0264-410X(97)00037-6

M3 - Article

C2 - 9302744

AN - SCOPUS:0030983864

VL - 15

SP - 1353

EP - 1357

JO - Vaccine

JF - Vaccine

SN - 0264-410X

IS - 12-13

ER -